BRAF, KRAS and EGFR Mutation Detection in Non-Small Cell Lung Cancer Patients Treated With Sorafenib Monotherapy
- To determine the mutation rates of BRAF, KRAS, and EGFR in patients with non-small cell
lung cancer treated with sorafenib tosylate on protocol ECOG-2501.
- To determine the association between BRAF, KRAS, or EGFR mutation status and clinical
benefits in patients treated with this regimen.
OUTLINE: This is a multicenter study.
DNA is isolated from archived plasma samples and analyzed for BRAF, KRAS, and EGFR
Mutation rate of sorafenib tosylate-target gene BRAF, and its upstream proteins KRAS and EGFR
Christine Chung, MD
Vanderbilt-Ingram Cancer Center